Research programme: Polo-like kinase 1 inhibitors - Cyclacel

Drug Profile

Research programme: Polo-like kinase 1 inhibitors - Cyclacel

Alternative Names: CYC 800 series; CYC-140; CYC800; Plk1 inhibitors - Cyclacel; Polo-like kinase 1 inhibitors - Cyclacel; Research programme: cell cycle modulators - Cyclacel

Latest Information Update: 06 Dec 2016

Price : $50

At a glance

  • Originator Cyclacel Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Mitosis inhibitors; Polo-like kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 01 Dec 2016 Cyclacel intends to submit an IND to the US FDA for CYC 140
  • 02 Apr 2012 Pharmacodynamics data from a preclinical study in Cancer presented at the 103rd Annual Meeting of the American Association for Cancer Research (AACR-2012)
  • 21 Apr 2010 Preclinical development is ongoing in Scotland
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top